Robert J. Kreitman
Laboratory of Molecular Biology
The Center for Cancer Research
United States of America
Biography
Dr. Kreitman received his M.D. from Ohio State University in 1985 and obtained his internal medicine residency training at Duke University from 1985 to 1988. He received his medical oncology fellowship training at the NIH from 1988 to 1991, has been working in the immunotoxin field since 1989, and has been directing clinical trials with immunotoxins since 1996. He also specializes in the treatment of hairy cell leukemia with immeunotoxins and other agents.
Research Interest
Clinical Research, Immunology
Publications
-
Kreitman RJ, Wilson W, Calvo KR, Arons E, Roth L, et al. (2013) Cladribine with immediate rituximab for the treatment of patients with variant hairy cell leukemia. Clin. Cancer Res. 19: 6873-6881.
-
Burotto M, Stetler-Stevenson M, Arons E, Zhou H, Wilson W et al. (2013) Bendamustine and rituximab in relapsed and refractory hairy cell leukemia. Clin. Cancer Res. 19: 6313-6321.
-
Xi L, Arons E, Navarro W, Calvo KR, Stetler et al. (2012) Both variant and IGHV4-34-expressing hairy cell leukemia lack the BRAF V600E mutation. Blood. 119: 3330-3332.
-
Kreitman RJ, Tallman MS, Robak T, Coutre S, Wilson WH, et al. (2012) Phase I trial of anti-CD22 recombinant immunotoxin moxetumomab pasudotox (CAT-8015 or HA22) in patients with hairy cell leukemia. J. Clin. Oncol. 119: 1822-1828.
